IBB News and Press, iShares Biotechnology ETF From 01/30/23

Summary Royalty Pharma plc is an interesting investment fund that buys pharmaceutical royalties and generates a non-correlated yield. With the depressed biotech sector valuation and increasing cost of capital with rising interest rates, we expect explosive growth in deal-making for Roya...

Summary Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. Seralutnib is entering phase 3 with an adapted design (with more severe patients); although the success is less clear, any positiv...

Summary According to the financial report of Johnson & Johnson, a partner of AbbVie, sales of Imbruvica decreased in the 4th quarter of 2022 due to increased competition. In less than six months, Humira's biosimilars will go on sale in the United States. Botox Cosmetic sales wer...

Summary Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2 asset for cannabis-related intoxication. ANEB-001 targets a cannabinoid intoxication; we do not believe the market potential for "acute intoxication" to be as lucrative as the...

Summary Ascendis is a mid-cap commercial biotech based in Denmark. Currently, it trades around $6.7B market cap, and the company holds $900M cash. Skytrofa (TransCon hGh) is Ascendis' lead approved agent for pediatric growth hormone deficiency (GHD), where the commercial update was luke...

Summary Relmada's second pivotal phase 3 trial of REL-1017 failed last December, which wasn't that surprising based on previous failure in monotherapy, RELIANCE 3. The third trial, RELIANCE 2, is ongoing, but with the recent two failures, we do not see much prospect of success. We d...

Summary Even in its battered condition, the therapeutics sub-sector still accounts for 9.1% of the Russell 2000 Growth index. M&A activity continues to heat up as big players—currently flush with cash—look to drive growth by filling their development pipelines. In ...

Summary scPharma is a small-cap biotech with a cardiology product, Furoscix, that was approved last October, expected to launch in 1Q 2023. We believe Furoscix is derisked as furosemide (loop diuretics) is the current standard of care, and the value proposition of SC dosage (over IV) is...

Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...

Summary CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40% growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTIC’s Vonjo (Pacritinib) is a differentiated late-stage JAK2/IRAK4/FLT3/CSF1R inhibitor for the treat...